MedPath

Micro-UltraSound In Cancer - Active Surveillance

Not Applicable
Recruiting
Conditions
Prostate Cancer
Registration Number
NCT05558241
Lead Sponsor
University of Alberta
Brief Summary

This study will compare the two imaging modalities (MRI and micro-ultrasound) during Active Surveillance of prostate cancer (PCa). Progression to clinically significant PCa will be assessed by first taking micro-US targeted samples (while blinded to MRI results), followed by MRI targeted samples, finishing with 12 systematic biopsy cores. The primary goal is to compare microUS to MRI for the detection of ≥GG2 PCa at confirmatory biopsy. This study will also collect blood samples from participants to be used for future biomarker studies.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
Male
Target Recruitment
210
Inclusion Criteria
  • Adult men with Gleason Grade Group 1 prostate cancer managed by active surveillance who require a confirmatory prostate biopsy
Exclusion Criteria
  • Men who cannot undergo a prostate MRI
  • Men who cannot undergo a prostate biopsy

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Cancer upgrading during Active surveillance by micro-ultrasound and MRIImmediately after biopsy.

The primary outcome will be detection of ≥Grade Group 2 by each biopsy, technique in combination with the systematic biopsy.

Secondary Outcome Measures
NameTimeMethod
Cancer upgrading during Active surveillance between imagine-guided versus systematic biopsy.Immediately after biopsy.

Secondary outcome will compare each imaged-guided biopsy technique to the standard-of-care 12 core systematic biopsy simultaneously obtained.

Trial Locations

Locations (5)

Humanitas

🇮🇹

Milan, Italy

University of California Los Angeles, Department of Urology

🇺🇸

Los Angeles, California, United States

Kipnes Urology Centre - Kaye Edmonton Clinic

🇨🇦

Edmonton, Alberta, Canada

University of British Columbia

🇨🇦

Vancouver, Alberta, Canada

CIUSSS du Nord-de-L'Ile-De-Montreal

🇨🇦

Montreal, Quebec, Canada

Humanitas
🇮🇹Milan, Italy
Nadia Lo Iacono
Contact
+39 0282247744
nadia.lo_iacono@cancercenter.humanitas.it
Nadia
Contact
Giovanni Lughezzani, MD, MD
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.